- Eli Lilly (LLY) leads the GLP-1 injectable market with tirzepatide (Mounjaro, Zepbound) and is developing retatrutide, which showed large weight-loss in trials and may launch in the U.S. by late 2027
- Eli Lilly (LLY) and Resilience invest $750M to expand Cincinnati manufacturing, add KwikPen production, create ~400 skilled jobs; site prep starts now, full operations expected early 2027
TradingView
Key facts: Eli Lilly (LLY) advances GLP-1; $750M Cincinnati expansion
- Sources
- TradingView
- Markets
- Stocks
- Active symbols
- NYSE:LLY
- Language
- English
Eli Lilly (LLY) leads the GLP-1 injectable market with tirzepatide (Mounjaro, Zepbound) and is developing retatrutide, which showed large weight-loss in trials and may launch in th